NCT00912275 - Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2008

Primary Completion Date

March 31, 2015

Study Completion Date

July 7, 2017

Conditions

Metastatic Breast Cancer

Interventions

DRUG

lapatinib plus oral vinorelbine

Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2

Trial Locations (1)

100

Department of Oncology,National Taiwan University Hospital, Taipei